TICKERNERD
Menu
SCNXSCNXHealthcare · Pharmaceutical Retailers

SCNX Stock Forecast: Scienture Holdings, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$0.43
−3.87% on the day

The 1 Wall Street analysts covering Scienture Holdings, Inc. hold a median 12-month price target of $1.5 — +246.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 8 of 100 as at 22 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$18.5M
Ticker Nerd rank
8 / 100
Median analyst target
$1.50
Analysts covering
1
Revenue$56K+449.1% y/y
Operating income−$3.5M
Net income−$3.4M
Free cash flow−$2.9M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.8%
1M
+17.2%
YTD
−15.2%
1Y
−58.0%
From 52W high
−83.4%
From 52W low
+79.5%
$0.24
$2.60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SCNX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scienture Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
8 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
89
Revisions
84
Momentum
25
Growth
8
Accruals
8
Issuance
4
Value
3
Volatility
2
Quality
1

Size (89): Smaller than most of the companies we track.

Quality (1): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SCNX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SCNX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.20$0.40$0.60$0.80$1.00$1.20$1.40$1.60Oct 25Jan 26Apr 26Jul 26SCNXHigh $1.50Median $1.50Low $1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $1.50Median $1.50High $1.50

The green dot is the last close — the median target sits +246.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 Feb 2026Maxim GroupInitiatesBuy$1.50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SCNX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SCNX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Scienture Holdings, Inc. returned −58.0% against +19.6% for the S&P 500, dividends included.

SCNX vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Oct 25Jan 26Apr 26Jul 26SCNXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SCNX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Scienture Holdings, Inc. (SCNX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.6×

Cheaper than 71% of US stocks

Price / sales
22.5×

Cheaper than 9% of US stocks

Price / book
0.3×

Cheaper than 89% of US stocks

EV / EBITDA
−1.7×

Cheaper than 70% of US stocks

Growth & margins
Revenue growth (YoY)
−133.4%

Higher than 1% of US stocks

Earnings growth (YoY)
449.1%

Higher than 95% of US stocks

Gross margin
95.6%

Higher than 99% of US stocks

Operating margin
−785.6%

Higher than 6% of US stocks

Net margin
76.8%

Higher than 98% of US stocks

Returns & dividend
Return on equity
−53.5%

Higher than 20% of US stocks

Return on assets
−8.9%

Higher than 27% of US stocks

Dividend yield
1339.3%

Higher than 99% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Scienture Holdings, Inc. (SCNX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scienture Holdings, Inc. has a market value of $18.5M and an enterprise value of $21.0M.

  • Revenue in the twelve months to 31 Mar 2026: $478K. The latest quarter shrank 133.4% year on year.

  • Net income over the same four quarters: −$41.9M, a −8761.3% net margin.

  • Free cash flow in the twelve months to 31 Mar 2026: −$13.3M.

  • Shares outstanding: 40.6M.

  • Trailing P/E: 0.6×; forward P/E: −7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1339.29%, paying out 0% of earnings.

  • Scienture Holdings, Inc. employs 4 people — $119K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

SCNX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPharmaceutical Retailers
CompanyMarket capTKN rank
SCNXScienture Holdings, Inc.$18.5M
8
PETSPetMed Express, Inc.$37.6M
40
HITIHigh Tide, Inc.$213.8M
73
CYCNCyclerion Therapeutics, Inc.*$18.2M
26
PLURPluri, Inc.*$18.5M
13
NMTCNeuroOne Medical Technologies Corp.*$18.5M
49
LEXXLexaria Bioscience Corp.*$18.0M
26

* Nearest Healthcare names by size — few pharmaceutical retailers companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scienture Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SCNX news & analysis

SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance

GlobeNewsWire · 14 Aug 2026positive

Scienture Holdings reported Q2 2026 results with approximately 510% sequential revenue growth from Q1 2026, a Q2 gross margin of approximately 97.7%, and an operating loss improving about 48% year-over-year to approximately $2.7 million. The company also commenced the commercial launch of REZENOPY™, its second commercial product.

Why it matters — SCNX watchers would care because the company reported strong sequential revenue growth, a near 98% gross margin, narrowed losses, and expansion of its commercial portfolio with a new product launch.

SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray

GlobeNewsWire · 12 Aug 2026positive

Scienture Holdings announced the commercial launch of REZENOPY™, the highest dose FDA-approved naloxone nasal spray, and has begun fulfilling initial purchase orders.

Why it matters — This milestone moves Scienture from product approval to actual revenue generation, marking a key operational step for the company's core product.

FAQ

Frequently asked questions about SCNX stock

What is the SCNX stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Scienture Holdings, Inc. have a median 12-month price target of $1.5, with estimates ranging from $1.5 to $1.5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SCNX stock a buy right now?

Of the 1 analysts covering Scienture Holdings, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scienture Holdings, Inc. 8 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SCNX?

As at 22 Aug 2026, Scienture Holdings, Inc. ranks 8 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (89 of 100).

Will SCNX stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +246.7% from the last close, and Ticker Nerd's factor model ranks Scienture Holdings, Inc. 8 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SCNX stock forecast for 2030?

No analyst covering Scienture Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCNX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $1.5 to $1.5 over the next 12 months.

How has SCNX stock performed over the past year?

Scienture Holdings, Inc. returned -58.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Scienture Holdings, Inc. do?

Scienture Holdings operates as a specialty pharmaceutical company through its wholly owned subsidiary Scienture, LLC, focusing on developing and commercializing branded pharmaceutical products for central nervous system and cardiovascular diseases in the United States. The company's current commercial portfolio includes Arbli, an FDA-approved oral suspension formulation of losartan potassium for treating hypertension and related cardiovascular conditions, and REZENOPY, a naloxone nasal spray for emergency opioid overdose treatment.

What is the latest news on SCNX?

The most recent item we track (GlobeNewsWire, 14 Aug 2026): "SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance". Scienture Holdings reported Q2 2026 results with approximately 510% sequential revenue growth from Q1 2026, a Q2 gross margin of approximately 97.7%, and an operating loss improving about 48% year-over-year to approximately $2.7 million. The company also commenced the commercial launch of REZENOPY™, its second commercial product.

Company

About Scienture Holdings, Inc.

Scienture Holdings operates as a specialty pharmaceutical company through its wholly owned subsidiary Scienture, LLC, focusing on developing and commercializing branded pharmaceutical products for central nervous system and cardiovascular diseases in the United States. The company's current commercial portfolio includes Arbli, an FDA-approved oral suspension formulation of losartan potassium for treating hypertension and related cardiovascular conditions, and REZENOPY, a naloxone nasal spray for emergency opioid overdose treatment. Scienture maintains a pipeline of investigational candidates spanning therapeutic areas including pain management and thrombosis. The company operates through two segments: Scienture, which focuses on branded pharmaceutical development and commercialization, and Integra, which engages in wholesale distribution of licensed pharmaceutical brands, generics, and non-drug products. Scienture has established partnerships with major wholesalers, health plans, and group purchasing organizations to distribute its products across retail, institutional, and long-term care settings. Founded in 2010 and based in the United States, the company leverages intellectual property protection, including patents listed in the FDA Orange Book, to support its specialty pharmaceutical strategy.

CEO Dr. Shankar Hariharan Ph.D. · 4 employees · United States · https://scienture.com